Details of the Drug Combinations

General Information of This Drug (ID: DM1KS78)

• Drug Name: Talazoparib (DM1KS78)
• Synonyms: Talazoparib (BMN 673); UNII-9QHX048FRV; 9QHX048FRV; Talazoparib [USAN:INN]; Talzenna; 4pjt; 2YQ

Indication

Breast cancer; ICD 11: 2C60-2C65; Status: Approved [1]; Psoriatic arthritis; ICD 11: FA21; Status: Phase 3 [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

16 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
CB-839 + Talazoparib	DCAI3T3	CB-839	Solid Tumor	[3]
Talazoparib + Talazoparib	DCHTNPD	Talazoparib	Advanced Solid Tumor	[4]
Talazoparib + Gemcitabine	DCXHMWM	Gemcitabine	Acute Myeloid Leukemia	[5]
Talazoparib + Belinostat	DC1DYWZ	Belinostat	Metastatic Breast Cancer	[6]
Talazoparib + Selinexor	DC7Y05T	Selinexor	Advanced Refractory Solid Tumors	[7]
Talazoparib + Tazemetostat	DC8HJ86	Tazemetostat	Metastatic Prostate Cancer	[8]
Talazoparib + Itraconazole	DCDSWL6	Itraconazole	Advanced Solid Tumors	[9]
Talazoparib + Decitabine	DCGGGYE	Decitabine	Leukemia	[10]
Talazoparib + Axitinib	DCGWDP7	Axitinib	Kidney Cancer	[11]
Talazoparib + Pacritinib	DCJ3JYK	Pacritinib	Primary Myelofibrosis	[12]
Talazoparib + Rifampicin	DCKM1N2	Rifampicin	Advanced Solid Tumors	[9]
Talazoparib + Arry-162	DCNKPA6	Arry-162	Pancreatic Cancer	[13]
Talazoparib + Decitabine	DCPM4TM	Decitabine	Acute Myeloid Leukemia	[14]
Talazoparib + PF-05212384	DCXWFUO	PF-05212384	TNBC - Triple-Negative Breast Cancer	[15]
Talazoparib + Enzalutamide	DCS7RT7	Enzalutamide	Metastatic Prostate Cancer	[16]
Talazoparib + Temozolomide	DCSTKPV	Temozolomide	Ovarian Cancer	[17]

References

• [1] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8313).
• [3] ClinicalTrials.gov (NCT03875313) Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
• [4] ClinicalTrials.gov (NCT05898399) Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
• [5] ClinicalTrials.gov (NCT05101551) Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
• [6] ClinicalTrials.gov (NCT04703920) Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
• [7] ClinicalTrials.gov (NCT05035745) Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
• [8] ClinicalTrials.gov (NCT04846478) Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
• [9] ClinicalTrials.gov (NCT03077607) A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors
• [10] ClinicalTrials.gov (NCT03974217) Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
• [11] ClinicalTrials.gov (NCT04337970) Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
• [12] ClinicalTrials.gov (NCT06218628) Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
• [13] ClinicalTrials.gov (NCT03637491) A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
• [14] ClinicalTrials.gov (NCT02878785) Decitabine and Talazoparib in Untreated AML and R/R AML
• [15] ClinicalTrials.gov (NCT03911973) Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
• [16] ClinicalTrials.gov (NCT04332744) Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)
• [17] ClinicalTrials.gov (NCT02836028) A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer